stockrowVAREX IMAGING
VREX Healthcare Medical Devices
VAREX IMAGING’s revenue for fiscal 2025 (year ended September 2025) was $844.6 million, up 4.14% from fiscal 2024.
- Revenue
- +3.69%
- EPS
- +117.2%
- Free cash flow
- +757.1%
- Total debt
- −5.55%
Quarter to June 2026, against a year earlier
Follow VREX
Alert me
VAREX IMAGING (VREX) EV/Sales
As of 5 November 2026, VAREX IMAGING (VREX) trades at a EV/Sales of 1.2×. Over the past ten years it has ranged from 0.6× (August 2025) to 2.8× (December 2017); the current reading is higher than 30% of that period. That is below the Medical Devices industry median of 2.7× and below the Healthcare sector median of 3.5×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 0.9× | (4.44%) |
| FY2024 | 0.9× | (19.53%) |
| FY2023 | 1.1× | (17.67%) |
| FY2022 | 1.4× | (20.59%) |
| FY2021 | 1.7× | 48.75% |
| FY2020 | 1.1× | (38.38%) |
| FY2019 | 1.9× | 3.32% |
| FY2018 | 1.8× | (25.39%) |
| FY2017 | 2.4× | 52.71% |
| FY2016 | 1.6× | 0.00% |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 0.8× | (3.39%) |
| Mar 2026 | 0.8× | (3.65%) |
| Dec 2025 | 0.9× | (0.71%) |
| Sep 2025 | 0.9× | 22.81% |
| 39 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| INMD InMode Ltd. compare | 0.8× |
| AHCO AdaptHealth Corp. compare | 0.8× |
| VREX VAREX IMAGING | 1.2× |
| QDEL QuidelOrtho Corporation compare | 1.4× |
| BVS Bioventus Inc. compare | 1.6× |
| CTKB Cytek Biosciences, Inc. compare | 2.2× |
| KIDS OrthoPediatrics Corp. compare | 3.1× |
| BBNX Beta Bionics, Inc. compare | 3.8× |
| PACB Pacific Biosciences of California, Inc. compare | 7.5× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.5× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)